Robert K Flamm

Summary

Affiliation: JMI Laboratories
Country: USA

Publications

  1. Flamm R, Sader H, Farrell D, Jones R. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob Agents Chemother. 2012;56:2933-40 pubmed publisher
  2. Flamm R, Mendes R, Ross J, Sader H, Jones R. Linezolid surveillance results for the United States: LEADER surveillance program 2011. Antimicrob Agents Chemother. 2013;57:1077-81 pubmed publisher
    ..The "all organism" linezolid-resistant and nonsusceptible rate was only 0.19%. ..
  3. Flamm R, Rhomberg P, Jones R, Farrell D. In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59:2280-5 pubmed publisher
    ..0% susceptible) and 4-fold more active than tigecycline (MIC90, 4 μg/ml). This novel agent merits further exploration of its potential against multidrug-resistant Gram-negative bacteria. ..
  4. Flamm R, Rhomberg P, Kaplan N, Jones R, Farrell D. Activity of Debio1452, a FabI inhibitor with potent activity against Staphylococcus aureus and coagulase-negative Staphylococcus spp., including multidrug-resistant strains. Antimicrob Agents Chemother. 2015;59:2583-7 pubmed publisher
    ..004 μg/ml) than the other agents tested against these staphylococcal species, which included dominant MRSA clones and strains resistant to currently utilized antimicrobial agents. ..
  5. Flamm R, Rhomberg P, Farrell D, Jones R. In vitro spectrum of pexiganan activity; bactericidal action and resistance selection tested against pathogens with elevated MIC values to topical agents. Diagn Microbiol Infect Dis. 2016;86:66-9 pubmed publisher
  6. Flamm R, Mendes R, Hogan P, Streit J, Ross J, Jones R. Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014). Antimicrob Agents Chemother. 2016;60:2273-80 pubmed publisher
    ..Linezolid demonstrated excellent activity and a sustained susceptibility rate of 99.78% overall. ..
  7. Flamm R, Nichols W, Sader H, Farrell D, Jones R. In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients. Int J Antimicrob Agents. 2016;47:235-42 pubmed publisher
    ..Ceftazidime/avibactam was generally active against a high proportion of isolates resistant to ceftazidime from PHP and VAPB patients. ..
  8. Flamm R, Jones R, Sader H. In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011). J Glob Antimicrob Resist. 2014;2:183-189 pubmed publisher
    ..Overall, ceftaroline demonstrated in vitro activity against pathogens isolated from various infection sites, including respiratory tract, bloodstream, and skin and skin-structure infections, across the monitored nations. ..
  9. Flamm R, Rhomberg P, Huband M, Farrell D. In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2016;60:6381-5 pubmed publisher
    ..MIC50 and MIC90 values against all S. pneumoniae isolates were 0.008 and 0.015 μg/ml. Delafloxacin susceptibility was not affected by β-lactamase status against H. influenzae and M. catarrhalis. ..

More Information

Publications21

  1. Flamm R, Castanheira M, Streit J, Jones R. Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia, and Burkholderia cepacia species complex isolates from a global surveillance program (2013). Diagn Microbiol Infect Dis. 2016;85:352-355 pubmed publisher
    ..Minocycline, particularly the intravenous formulation, has activity against several ESKAPE pathogens and merits consideration in seriously ill patients where treatment options may be limited due to the presence of MDR bacteria. ..
  2. Flamm R, Farrell D, Mendes R, Ross J, Sader H, Jones R. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagn Microbiol Infect Dis. 2012;74:54-61 pubmed publisher
    ..The LEADER program continues to provide valuable reference and molecular-level monitoring of linezolid activity. ..
  3. Flamm R, Rhomberg P, Simpson K, Farrell D, Sader H, Jones R. In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms. Antimicrob Agents Chemother. 2015;59:1751-4 pubmed publisher
    ..The "all organism" MIC90 of 32 μg/ml for pexiganan in this study was >250-fold below the pexiganan concentration in the cream/delivery vehicle being developed for topical use. ..
  4. Flamm R, Mendes R, Ross J, Sader H, Jones R. An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011. Diagn Microbiol Infect Dis. 2013;76:206-13 pubmed publisher
    ..As the activities of commonly used antimicrobials continue to be compromised by evolving resistance mechanisms in Gram-positive pathogens, linezolid-resistant strains remain uncommon and without increasing occurrence. ..
  5. Pfaller M, Rhomberg P, Huband M, Flamm R. Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe. Antimicrob Agents Chemother. 2017;61: pubmed publisher
    ..The potent activity of omadacycline against S. aureus indicates that omadacycline merits further study in serious infections where multidrug resistance may be a concern. ..
  6. Pfaller M, Huband M, Rhomberg P, Flamm R. Surveillance of Omadacycline Activity against Clinical Isolates from a Global Collection (North America, Europe, Latin America, Asia-Western Pacific), 2010-2011. Antimicrob Agents Chemother. 2017;61: pubmed publisher
  7. Flamm R, Farrell D, Rhomberg P, Scangarella Oman N, Sader H. Gepotidacin (GSK2140944) In Vitro Activity against Gram-Positive and Gram-Negative Bacteria. Antimicrob Agents Chemother. 2017;61: pubmed publisher
  8. Flamm R, Mendes R, Hogan P, Ross J, Farrell D, Jones R. In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. Diagn Microbiol Infect Dis. 2015;81:283-9 pubmed publisher
    ..aureus and 1 E. faecium) harbored the cfr resistance mechanism. The findings indicate that linezolid activity remains stable, although there are examples of clonal dissemination within several monitored institutions. ..
  9. Farrell D, Sader H, Rhomberg P, Scangarella Oman N, Flamm R. In Vitro Activity of Gepotidacin (GSK2140944) against Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2017;61: pubmed publisher
    ..5 to >2.5 h, and the PAE-SME was >2.5 h. These in vitro data indicate that further study of gepotidacin is warranted for potential use in treating infections caused by N. gonorrhoeae. ..
  10. Pfaller M, Sader H, Rhomberg P, Flamm R. In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother. 2017;61: pubmed publisher
    ..Delafloxacin was shown to be active against organisms that may be encountered in acute bacterial skin and skin structure infections, respiratory infections, and urinary tract infections. ..
  11. Flamm R, Rhomberg P, Sader H. In Vitro Activity of the Novel Lactone Ketolide Nafithromycin (WCK 4873) against Contemporary Clinical Bacteria from a Global Surveillance Program. Antimicrob Agents Chemother. 2017;61: pubmed publisher
    ..Overall, nafithromycin showed potent in vitro activity against a broad range of contemporary (2014) global pathogens. These results support the continued clinical development of nafithromycin for treatment of CABP. ..
  12. Flamm R, Sader H, Castanheira M, Jones R. The application of in vitro surveillance data for antibacterial dose selection. Curr Opin Pharmacol. 2017;36:130-138 pubmed publisher
    ..These data enable the optimal use of antibacterial agents in an environment in which we face changing and challenging bacterial pathogens. ..